Quebec – Sherbrooke – Fleurimont
Corporation
www.tranzyme.com
Quebec
Sherbrooke
Fleurimont
Corporation
active
Tranzyme Pharma is a clinical-stage biopharmaceutical company which discovers and develops breakthrough small molecule drugs for diseases where there is a high unmet medical need. Tranzyme is developing a pipeline of novel drugs for the treatment of gastrointestinal and metabolic diseases. The Company€™s lead product, TZP-101, is a potent ghrelin agonist that is currently in two Phase IIb clinical trials for post-operative ileus and severe gastroparesis; TZP-101 has been granted fast track designation for severe gastroparesis by the FDA. The Company is also developing first-in-class therapeutics for chronic gastroparesis and other GI dysmotility disorders (TZP-102), severe diarrhea associated with cancer and infectious disease (TZP-201), and obesity (TZP-301).
Country of Ownership: Foreign
Year Established: 1996
Exporting: Yes
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Services
Services:
Biotechnology
Technology:
Tranzyme Pharma has discovered and optimized its therapeutic candidates using its versatile proprietary drug discovery technology, Macrocyclic Template Chemistry (MATCHâ„¢), which exploits a novel class of small molecule compounds called macrocycles. MATCHâ„¢ is an attractive source of novel drugs as it maintains the favorable characteristics exhibited by large biomolecules, such as tight receptor binding for high potency and selectivity, while eliminating the drawbacks typically associated with peptide drugs, i.e. poor metabolic stability, low oral bioavailability, high manufacturing costs, and antigenicity.
Tranzyme has developed the first synthetic library of these low molecular weight macrocyclic compounds, containing over 25,000 unique structures. The major characteristics of MATCHâ„¢ are: - Produces drug-like compounds with demonstrated oral bioavailability, metabolic stability and aqueous solubility
- Ability to find both agonists and antagonists
- Rapid synthesis of focused libraries providing accelerated, resource-efficient lead optimization
Sector:
Classification Codes
Dun and Bradstreet Number: 783646248
Distribution of Employees
The Company maintains U.S. and Canadian operations. The North Carolina site serves as the corporate headquarters and the center for business development, clinical development and regulatory activities. The medicinal chemistry, lead optimization, pharmacology and preclinical development activities are based in Quebec. In total, the Company employs 43 people, including 34 in research and development.
Castaigne Jean-Paul
Corcoran Donald
Davidson Aaron
Drutz David
Eisenstadt Richard
No associations
LandOfFree
Tranzyme Pharma Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with Tranzyme Pharma Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tranzyme Pharma Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-23814